Back to Journals » OncoTargets and Therapy » Volume 14
RETRACTED ARTICLE: Bergamottin Induces DNA Damage and Inhibits Malignant Progression in Melanoma by Modulating miR-145/Cyclin D1 Axis
Received 12 November 2020
Accepted for publication 19 May 2021
Published 17 June 2021 Volume 2021:14 Pages 3769—3781
DOI https://doi.org/10.2147/OTT.S275322
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Alberto Bongiovanni
This paper has been retracted.
Zhao Z, Liao N. Onco Targets Ther. 2021;14:3769–3781. https://doi.org/10.2147/OTT.S275322
We, the Editors and Publisher of the journal OncoTargets and Therapy, have retracted the published article.
After publication, concerns have been raised by a third party in 2026 about the integrity of the data in Figures 2, 5, 6, and 7 of the article.
Further investigation conducted by the Journal and Publisher confirmed the following:
- Unexpected similarities between the cell staining images in Figure 2 that are representative of different samples and treatment conditions
- Unexpected similarities between the flow cytometry plots in Figures 3B and 6F that are representative of different samples and treatment conditions
- Unexpected similarities between the Western blots in Figures 5G and 6B that are representative of different samples and treatment conditions
- Unexpected similarities between the immunohistochemistry staining images in Figure 7 that are representative of different samples and treatment conditions
When informed that concerns had been raised, the authors checked their data and confirmed there are fundamental errors present. The authors have requested the retraction of this article and apologise for the errors.
We have been informed in our decision-making by our editorial policies and the COPE guidelines.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms
and incorporate the Creative Commons Attribution
- Non Commercial (unported, 3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
